Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology (Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on breast cancer therapies, has granted stock options to four new employees. The grants total 154,500 shares of common stock with an exercise price of $4.37 per share.
The stock options, approved under the company's 2022 Inducement Plan, will vest over four years, with 25% vesting in the first year and the remainder vesting monthly over three years. The options have a 10-year term and were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), un'azienda biofarmaceutica in fase clinica specializzata in terapie per il cancro al seno, ha concesso opzioni su azioni a quattro nuovi dipendenti. Le concessioni ammontano a 154.500 azioni ordinarie con un prezzo di esercizio di 4,37 dollari per azione.
Le opzioni su azioni, approvate nell'ambito del Piano di Incentivazione 2022 dell'azienda, matureranno in un periodo di quattro anni, con il 25% che matura nel primo anno e il resto che matura mensilmente nei successivi tre anni. Le opzioni hanno una durata di 10 anni e sono state concesse in conformità alla Regola di quotazione Nasdaq 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), una empresa biofarmacéutica en etapa clínica enfocada en terapias para el cáncer de mama, ha otorgado opciones sobre acciones a cuatro nuevos empleados. Las concesiones suman un total de 154,500 acciones ordinarias con un precio de ejercicio de $4.37 por acción.
Las opciones sobre acciones, aprobadas bajo el Plan de Incentivos 2022 de la compañía, se consolidarán durante cuatro años, con un 25% consolidándose en el primer año y el resto consolidándose mensualmente durante los siguientes tres años. Las opciones tienen un plazo de 10 años y fueron otorgadas de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
Olema Oncology (Nasdaq: OLMA)는 유방암 치료에 중점을 둔 임상 단계의 생명공학 제약 회사로서 네 명의 신입 직원에게 주식 매수선택권을 부여했습니다. 총 154,500주의 보통주가 부여되었으며, 행사가격은 주당 4.37달러입니다.
이 주식 매수선택권은 회사의 2022년 유인 계획에 따라 승인되었으며, 4년에 걸쳐 권리가 취득됩니다. 첫 해에 25%가 취득되며 나머지는 3년 동안 매월 취득됩니다. 옵션의 유효 기간은 10년이며, Nasdaq 상장 규칙 5635(c)(4)에 따라 부여되었습니다.
Olema Oncology (Nasdaq : OLMA), une société biopharmaceutique en phase clinique spécialisée dans les thérapies contre le cancer du sein, a attribué des options d'achat d'actions à quatre nouveaux employés. Les attributions totalisent 154 500 actions ordinaires avec un prix d'exercice de 4,37 $ par action.
Les options d'achat d'actions, approuvées dans le cadre du Plan d'incitation 2022 de la société, seront acquises sur une période de quatre ans, avec 25 % acquises la première année et le reste acquis mensuellement sur les trois années suivantes. Les options ont une durée de 10 ans et ont été accordées conformément à la règle de cotation Nasdaq 5635(c)(4).
Olema Oncology (Nasdaq: OLMA), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Brustkrebstherapien, hat Aktienoptionen an vier neue Mitarbeiter gewährt. Die Zuteilungen umfassen insgesamt 154.500 Stammaktien mit einem Ausübungspreis von 4,37 USD pro Aktie.
Die Aktienoptionen, genehmigt im Rahmen des Inducement-Plans 2022 des Unternehmens, werden über einen Zeitraum von vier Jahren unverfallbar, wobei 25 % im ersten Jahr und der Rest monatlich über drei Jahre unverfallbar werden. Die Optionen haben eine Laufzeit von 10 Jahren und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date for such employee and the remainder vesting in 36 equal monthly installments over the following three years, subject to the employee being continuously employed by Olema as of such vesting dates. The stock options have a 10-year term and an exercise price of
Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), currently in a Phase 3 clinical trial called OPERA-01. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical trial. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com
FAQ
What stock options did Olema Oncology (OLMA) grant to new employees in July 2025?
What is the vesting schedule for Olema Oncology's July 2025 employee stock options?
What is the exercise price of Olema Oncology's July 2025 inducement grants?
Under what plan were Olema Oncology's July 2025 stock options granted?
